Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Stanford - cephalexin selected renal/HD rows
Product / population
Adult oral cephalexin; selected rows from institutional antimicrobial guide.
Renal method
CrCl, mL/min; intermittent HD assumes three sessions weekly.
Source revision
ABX Subcommittee approved February 2026 (cover page visually inspected)
Retrieved
2026-09-07
Local review status
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Label maximum differs from institution-specific bacteremia dosing
The KEFLEX renal table caps the daily dose in moderate impairment. UCSF uses a different high-dose strategy for selected gram-negative bloodstream infection; Stanford also has a distinct HD regimen.
What to reconcile: The indication and regimen must stay together. Do not average the doses or relabel the bloodstream-infection schedule as a general renal dose.
Source difference identified; final patient-specific adjudication required.
Label daily cap versus indication-specific institutional bloodstream doses
KEFLEX limits total daily dose to 1 g at CrCl 30-59 and has insufficient HD adjustment information. UCSF uses higher selected Gram-negative bloodstream-infection doses and supplies an intermittent-HD row.
What to reconcile: Assess infection eligibility, organism susceptibility, patient setting and institutional policy. Keep the complete institutional regimen separate from the label; do not transfer the bloodstream schedule to routine cystitis or children.
Stanford Health Care · Adult oral cephalexin; selected rows from institutional antimicrobial guide.
Renal method: CrCl, mL/min; intermittent HD assumes three sessions weekly. Source date: ABX Subcommittee approved February 2026 (cover page visually inspected) Retrieved: 2026-09-07
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
For CrCl 15-29, the guide lists 250 mg orally every 8-12 hours. For CrCl 5-14, it lists 250 mg every 24 hours. For intermittent HD, it lists 500 mg orally every 24 hours, administered daily but after HD on dialysis days. No CRRT data are listed. Do not substitute the UCSF bacteremia regimen or label regimen without considering indication and institutional policy.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.